DE602005006294D1 - Reinigungsverfahren für bakterielles cytolysin - Google Patents

Reinigungsverfahren für bakterielles cytolysin

Info

Publication number
DE602005006294D1
DE602005006294D1 DE602005006294T DE602005006294T DE602005006294D1 DE 602005006294 D1 DE602005006294 D1 DE 602005006294D1 DE 602005006294 T DE602005006294 T DE 602005006294T DE 602005006294 T DE602005006294 T DE 602005006294T DE 602005006294 D1 DE602005006294 D1 DE 602005006294D1
Authority
DE
Germany
Prior art keywords
bacterial cytolysin
salt
extract
cytolysin
cleaning procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005006294T
Other languages
English (en)
Other versions
DE602005006294T2 (de
Inventor
Ralph L Biemans
Carine Goraj
Emmanuel Mertens
A Vandercammen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE602005006294D1 publication Critical patent/DE602005006294D1/de
Application granted granted Critical
Publication of DE602005006294T2 publication Critical patent/DE602005006294T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
DE602005006294T 2004-09-22 2005-09-20 Reinigungsverfahren für bakterielles cytolysin Active DE602005006294T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0421083 2004-09-22
GBGB0421083.7A GB0421083D0 (en) 2004-09-22 2004-09-22 Purification process
PCT/EP2005/010258 WO2006032499A1 (en) 2004-09-22 2005-09-20 Purification process for bacterial cytolysin

Publications (2)

Publication Number Publication Date
DE602005006294D1 true DE602005006294D1 (de) 2008-06-05
DE602005006294T2 DE602005006294T2 (de) 2008-08-14

Family

ID=33397075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005006294T Active DE602005006294T2 (de) 2004-09-22 2005-09-20 Reinigungsverfahren für bakterielles cytolysin

Country Status (15)

Country Link
US (1) US20070231876A1 (de)
EP (1) EP1791860B1 (de)
JP (1) JP4934591B2 (de)
AT (1) ATE393165T1 (de)
CA (1) CA2580113C (de)
CY (1) CY1107960T1 (de)
DE (1) DE602005006294T2 (de)
DK (1) DK1791860T3 (de)
ES (1) ES2304724T3 (de)
GB (1) GB0421083D0 (de)
HR (1) HRP20080242T3 (de)
PL (1) PL1791860T3 (de)
PT (1) PT1791860E (de)
SI (1) SI1791860T1 (de)
WO (1) WO2006032499A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009579A (es) 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TWI465248B (zh) 2005-12-22 2014-12-21 Glaxosmithkline Biolog Sa 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
AU2007281044A1 (en) * 2006-08-03 2008-02-07 Newcastle Innovation Limited Treatment and prevention of allergic airways diseases
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
US8226959B2 (en) 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
EP2865752A1 (de) 2009-09-03 2015-04-29 Pfizer Vaccines LLC PCSK9-Impfstoff
JP5944480B2 (ja) * 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
JP5917682B2 (ja) * 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
NZ760783A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
AU2016295566B2 (en) 2015-07-21 2019-06-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3377098A1 (de) 2015-11-20 2018-09-26 Pfizer Inc Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
JP7001686B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
CA3087572A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2021522213A (ja) 2018-04-18 2021-08-30 エスケー バイオサイエンス カンパニー リミテッド ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
EP3894431A2 (de) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modifizierte trägerproteine zur o-verknüpften glykosylierung
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4003410A1 (de) 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Multivalente pneumokokken-polysaccharid-protein-konjugat-zusammensetzungen und verfahren zu ihrer verwendung
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
EP4232593A1 (de) 2020-10-22 2023-08-30 Pfizer Inc. Verfahren zur reinigung von bakteriellen polysacchariden
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2178A1 (fr) * 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
US5652125A (en) * 1996-06-10 1997-07-29 Pharmacia S.P.A. Process for preparing daunorubicin
EP0998557A2 (de) * 1997-07-21 2000-05-10 North American Vaccine, Inc. Modifizierte immunogene pneumolysin, deren zusammensetzungen und deren verwendungen als impfung
MXPA05009579A (es) * 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物

Also Published As

Publication number Publication date
GB0421083D0 (en) 2004-10-27
HRP20080242T3 (en) 2008-09-30
PT1791860E (pt) 2008-05-20
CY1107960T1 (el) 2013-09-04
WO2006032499A1 (en) 2006-03-30
CA2580113A1 (en) 2006-03-30
ATE393165T1 (de) 2008-05-15
JP4934591B2 (ja) 2012-05-16
EP1791860A1 (de) 2007-06-06
US20070231876A1 (en) 2007-10-04
PL1791860T3 (pl) 2008-09-30
DK1791860T3 (da) 2008-07-14
SI1791860T1 (sl) 2008-08-31
EP1791860B1 (de) 2008-04-23
JP2008513408A (ja) 2008-05-01
CA2580113C (en) 2018-01-16
DE602005006294T2 (de) 2008-08-14
ES2304724T3 (es) 2008-10-16

Similar Documents

Publication Publication Date Title
DE602005006294D1 (de) Reinigungsverfahren für bakterielles cytolysin
CR8997A (es) Produccion de polipeptidos
CR8998A (es) PRODUCCION DE TNFR-Ig Y FUSION DE PROTEINA
CR8996A (es) PRODUCCION DE a-BETA
UA92157C2 (ru) Способ продуцирования гормона роста
NZ591292A (en) Improved cell composition and methods of making the same
MY163480A (en) Sclerostin binding agents
ZA200904482B (en) Polyelectrolyte precipitation and purification of antibodies
EP0976829A3 (de) Protein-deamiderendes Enzym, dafür kodierendes Gen, Verfahren zur Herstellung und Verwendung davon
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
ATE324030T1 (de) Brassica-transformation durch teilchenbeschuss
NZ593239A (en) Fusion Collagenase in which affinity TAG is linked and method for producing the same
DK1620549T3 (da) Fremgangsmåde til fremstilling af biologiske stoffer ved perfusionsdyrkning af suspenderede dyreceller
DE602005007476D1 (de) Verfahren zur reinigung von oozysten mittels enzymatischer verdauung von faeces
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
EP1687413B8 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
MXPA02010147A (es) Antagonistas cd40 para uso en el tratamiento de psoriasis y otras condiciones inflamatorias de la piel.
WO2004011637A3 (en) Modified adamts4 molecules and method of use thereof
CA2365626A1 (en) High production method of prenyl alcohol by microorganisms
GB2425312A (en) Method for cell surface display of target proteins using fadl of e coli
ATE415470T1 (de) Herstellungsverfahren für iturin a und dessen homologe
WO2004015091A3 (en) Preparation of type ii pneumocytes from stem cells
CA2758228C (en) Method for reducing methoxypyrazines in grapes and grape products
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: VANDERCAMMEN, A., RIXENSART, BE

Inventor name: GORAJ, CARINE, RIXENSART, BE

Inventor name: BIEMANS, RALPH L., RIXENSART, BE

Inventor name: MERTENS, EMMANUEL, RIXENSART, BE

8364 No opposition during term of opposition